GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Total Current Liabilities

TuHURA Biosciences (TuHURA Biosciences) Total Current Liabilities : $2.87 Mil (As of Dec. 2022)


View and export this data going back to 2050. Start your Free Trial

What is TuHURA Biosciences Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. TuHURA Biosciences's total current liabilities for the quarter that ended in Dec. 2022 was $2.87

TuHURA Biosciences Total Current Liabilities Historical Data

The historical data trend for TuHURA Biosciences's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Total Current Liabilities Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22
Total Current Liabilities
7.15 2.87

TuHURA Biosciences Semi-Annual Data
Dec21 Dec22
Total Current Liabilities 7.15 2.87

TuHURA Biosciences Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

TuHURA Biosciences's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.754+0.117
+Other Current Liabilities+Current Deferred Liabilities
=0.00099999999999989+0
=2.87

TuHURA Biosciences's Total Current Liabilities for the quarter that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.754+0.117
+Other Current Liabilities+Current Deferred Liabilities
=0.00099999999999989+0
=2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

TuHURA Biosciences Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences (TuHURA Biosciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Total Current Liabilities
Comparable Companies
Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
Website
TuHURA Biosciences Inc is a clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies. The company's lead personalized cancer vaccine candidate, IFx-Hu2.0, is designed to prime the activation of the immune system to target and attack tumor cells by making them look like bacteria. Through an intratumoral injection of a gene coding for emm55, an immunogenic bacterial protein that is then expressed on the surface of tumor cells, the immune system is activated, providing a potent, multivalent systemic response against all neoantigens in a patient's tumor.

TuHURA Biosciences (TuHURA Biosciences) Headlines

No Headlines